Theodore J Lampidis

List of Publications by Year
in descending order

42	2,870	236925 25	315739 38
papers	citations	h-index	g-index

42	42	42	3831
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo. Cancer Research, 2004, 64, 31-34.	0.9	414
2	A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 523-530.	2.3	362
3	Under normoxia, 2-deoxy-<scp>d</scp>-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Molecular Cancer Therapeutics, 2007, 6, 3049-3058.	4.1	210
4	Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemotherapy and Pharmacology, 2004, 53, 116-122.	2.3	190
5	2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemotherapy and Pharmacology, 2011, 67, 899-910.	2.3	168
6	Differential Toxic Mechanisms of 2-Deoxy-D-Glucoseversus2-Fluorodeoxy-D -Glucose in Hypoxic and Normoxic Tumor Cells. Antioxidants and Redox Signaling, 2007, 9, 1383-1390.	5.4	136
7	Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-<scp>d</scp>-glucose. Molecular Cancer Therapeutics, 2007, 6, 732-741.	4.1	96
8	Antiangiogenic Activity of 2-Deoxy-D-Glucose. PLoS ONE, 2010, 5, e13699.	2.5	92
9	The wonders of 2â€deoxyâ€<scp>d</scp>â€glucose. IUBMB Life, 2014, 66, 110-121.	3.4	90
10	Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochemical Pharmacology, 2002, 64, 1745-1751.	4.4	77
11	The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 604-615.	4.1	73
12	Relevance of the chemical charge of rhodamine dyes to multiple drug resistance. Biochemical Pharmacology, 1989, 38, 4267-4271.	4.4	72
13	Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma. , 2008, 49, 2799.		69
14	Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing â€œhypoxic tumor cellsâ€• Cancer Chemotherapy and Pharmacology, 2006, 58, 725-734.	2.3	67
15	From delocalized lipophilic cations to hypoxia: Blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Molecular Nutrition and Food Research, 2009, 53, 68-75.	3.3	65
16	Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKÎ² leading to autophagy. Biochemical Pharmacology, 2013, 85, 1463-1477.	4.4	55
17	Inhibition of Akt Potentiates 2-DGâ€“Induced Apoptosis via Downregulation of UPR in Acute Lymphoblastic Leukemia. Molecular Cancer Research, 2012, 10, 969-978.	3.4	52
18	Activation of the Unfolded Protein Response by 2-Deoxy- <scp>d</scp> -Glucose Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication and Gene Expression. Antimicrobial Agents and Chemotherapy, 2012, 56, 5794-5803.	3.2	49

#	Article	IF	Citations
19	Effects of the mitochondrial probe rhodamine 123 and related analogs on the function and viability of pulsating myocardial cells in culture. Agents and Actions, 1984, 14, 751-757.	0.7	48
20	Differential Sensitivity to 2-Deoxy-D-glucose Between Two Pancreatic Cell Lines Correlates With GLUT-1 Expression. Pancreas, 2005, 30, e34-e39.	1.1	40
21	Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemotherapy and Pharmacology, 2014, 73, 417-427.	2.3	40
22	Ï0 tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochemical Pharmacology, 2000, 60, 1897-1905.	4.4	35
23	Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-<scp>d</scp>-glucose under hypoxia in lung cancer cell lines. Molecular Cancer Therapeutics, 2008, 7, 1506-1513.	4.1	33
24	Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer. Molecular Cancer Research, 2020, 18, 105-117.	3.4	33
25	Interaction of rhodamine 123 with mitochondria isolated from drug-sensitive and -resistant friend leukemia cells. Biochemical and Biophysical Research Communications, 1985, 127, 1039-1044.	2.1	31
26	<scp>ATF</scp>4 mediates necrosis induced by glucose deprivation and apoptosis induced by 2â€deoxyglucose in the same cells. FEBS Journal, 2015, 282, 3647-3658.	4.7	31
27	2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3Î² Activation. Molecular Cancer Therapeutics, 2016, 15, 264-275.	4.1	26
28	Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochemical Pharmacology, 2003, 65, 1419-1425.	4.4	22
29	Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose. Cancer Chemotherapy and Pharmacology, 2014, 73, 349-361.	2.3	21
30	Increased Hypoxia following Vessel Targeting in a Murine Model of Retinoblastoma. , 2009, 50, 5537.		20
31	Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 251-262.	2.3	19
32	Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress. Oncotarget, 2016, 7, 36461-36473.	1.8	19
33	High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemotherapy and Pharmacology, 2010, 66, 129-140.	2.3	18
34	Focal, Periocular Delivery of 2-Deoxy-<scp>d</scp>-Glucose as Adjuvant to Chemotherapy for Treatment of Advanced Retinoblastoma. , 2010, 51, 6149.		18
35	Models and discovery strategies for new therapies of retinoblastoma. Expert Opinion on Drug Discovery, 2013, 8, 383-394.	5.0	18
36	2â€Deoxyâ€<scp>d</scp>â€glucose exploits increased glucose metabolism in cancer and viralâ€infected cells: Relevance to its use in <scp>India</scp> against <scp>SARSâ€CoV</scp>â€2. IUBMB Life, 2021, 73, 1198-1204.	3.4	17

#	Article	IF	Citations
37	Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors. Clinical Ophthalmology, 2011, 5, 129.	1.8	11
38	Antiproliferative activity of taxol on human tumor and normal breast cellsvs. effects on cardiac cells. International Journal of Cancer, 1995, 60, 571-575.	5.1	10
39	Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress. Leukemia Research, 2015, 39, 1246-1254.	0.8	10
40	Î±-Smooth muscle actin expression in cultured cardiac fibroblasts of newborn rat. In Vitro Cellular & Developmental Biology, 1992, 28, 293-296.	1.0	9
41	Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors. Clinical Ophthalmology, 2012, 6, 817.	1.8	4
42	BCR-ABL+ Bp-ALL Exhibits Heightened Sensitivity to Simultaneous Induction of Energy and ER Stress Via Downregulation of Mcl-1 Expression. Blood, 2014, 124, 916-916.	1.4	0